OBJECTIVE: To estimate the risk of high-grade squamous intraepithelial lesions (HSIL) in adolescents with HIV. MATERIALS AND METHODS: Review of cervical cytology and biopsy results from women aged 20 years and younger obtained within 3 years of enrollment in a prospective multicenter study. RESULTS: At enrollment, none of 132 adolescent participants (45 HIV seropositive and 87 seronegative) had HSIL or cervical intraepithelial neoplasia grade 2 or 3 (CIN 2,3). Eight (7%) of 123 women with follow-up developed high-grade disease after a median of 2.6 years of observation. The incidence of HSIL/CIN 2,3 was 2.7/100 person-years (4.8/100 person-years in HIV seropositive and 1.6/100 person-years in HIV seronegative women; relative risk = 3.1; 95% CI = 0.76-12.74; p =.13). No cancers were found in adolescents during the study. CONCLUSIONS: The low incidence of HSIL or CIN 2,3 in adolescents suggests that optimal management is careful observation rather than preventive treatment of low-grade abnormalities.
OBJECTIVE: To estimate the risk of high-grade squamous intraepithelial lesions (HSIL) in adolescents with HIV. MATERIALS AND METHODS: Review of cervical cytology and biopsy results from women aged 20 years and younger obtained within 3 years of enrollment in a prospective multicenter study. RESULTS: At enrollment, none of 132 adolescent participants (45 HIV seropositive and 87 seronegative) had HSIL or cervical intraepithelial neoplasia grade 2 or 3 (CIN 2,3). Eight (7%) of 123 women with follow-up developed high-grade disease after a median of 2.6 years of observation. The incidence of HSIL/CIN 2,3 was 2.7/100 person-years (4.8/100 person-years in HIV seropositive and 1.6/100 person-years in HIV seronegative women; relative risk = 3.1; 95% CI = 0.76-12.74; p =.13). No cancers were found in adolescents during the study. CONCLUSIONS: The low incidence of HSIL or CIN 2,3 in adolescents suggests that optimal management is careful observation rather than preventive treatment of low-grade abnormalities.
Authors: Anna-Barbara Moscicki; Stephen Shiboski; Nancy K Hills; Kimberly J Powell; Naomi Jay; Evelyn N Hanson; Susanna Miller; K Lisa Canjura-Clayton; Sepidah Farhat; Jeanette M Broering; Teresa M Darragh Journal: Lancet Date: 2004 Nov 6-12 Impact factor: 79.321
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: A B Moscicki; N Hills; S Shiboski; K Powell; N Jay; E Hanson; S Miller; L Clayton; S Farhat; J Broering; T Darragh; J Palefsky Journal: JAMA Date: 2001-06-20 Impact factor: 56.272
Authors: L S Massad; K A Riester; K M Anastos; R G Fruchter; J M Palefsky; R D Burk; D Burns; R M Greenblatt; L I Muderspach; P Miotti Journal: J Acquir Immune Defic Syndr Date: 1999-05-01 Impact factor: 3.731
Authors: L S Massad; L Ahdieh; L Benning; H Minkoff; R M Greenblatt; H Watts; P Miotti; K Anastos; M Moxley; L I Muderspach; S Melnick Journal: J Acquir Immune Defic Syndr Date: 2001-08-15 Impact factor: 3.731
Authors: J Martinez; R Smith; M Farmer; J Resau; L Alger; R Daniel; J Gupta; K Shah; Z Naghashfar Journal: Pediatrics Date: 1988-10 Impact factor: 7.124
Authors: Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon Journal: Am J Obstet Gynecol Date: 2007-10 Impact factor: 8.661